Viagra vs Vardenafil (Levitra/Staxyn): Long-Term Durability of Response

What Are Sildenafil and Vardenafil, and How Do They Work?

Both sildenafil and vardenafil inhibit phosphodiesterase type 5 (PDE5), the enzyme that degrades cyclic GMP in corpus cavernosum smooth muscle. When cyclic GMP accumulates, smooth muscle relaxes, blood flow increases, and an erection becomes possible in response to sexual stimulation. Neither drug works without arousal. The two molecules differ structurally, which produces measurable differences in PDE5 selectivity, half-life, and interaction with food.

Selectivity Ratios and Their Clinical Meaning

Sildenafil inhibits PDE6 (found in retinal photoreceptors) at roughly 10-fold lower concentrations than vardenafil does. That difference partly explains why some men on sildenafil report transient blue-tinged vision or photosensitivity. Vardenafil has an approximately 15-fold higher selectivity for PDE5 over PDE6 compared with sildenafil, which may translate to fewer visual side effects at therapeutically equivalent doses. Neither drug is without off-target effects, but the selectivity gap is clinically relevant for men who are already managing retinal disease.

Half-Life and the Practical Dosing Window

Sildenafil has a plasma half-life of approximately 3 to 5 hours. Vardenafil's half-life is similar, approximately 4 to 5 hours, though some pharmacokinetic models place it slightly longer in older men. The orodispersible Staxyn formulation reaches a higher peak plasma concentration (Cmax) than the equivalent tablet dose of Levitra, because buccal absorption bypasses some first-pass metabolism. A 2006 pharmacokinetic study published in the British Journal of Clinical Pharmacology found that Staxyn 10 mg produced a Cmax roughly 1.4-fold higher than Levitra 10 mg tablet in healthy volunteers, though overall bioavailability (AUC) was comparable. [1]

Food and Alcohol Interactions

High-fat meals delay sildenafil absorption by up to 60 minutes and reduce peak plasma concentration by approximately 29%. Vardenafil tablet (Levitra) is similarly affected by high-fat meals. The Staxyn orodispersible tablet, however, must be taken on an empty stomach: a high-fat meal reduces its AUC by roughly 50%. Both drugs interact with alcohol in a dose-dependent way, amplifying hypotensive effects. Clinicians should ask specifically about pre-intimacy alcohol consumption before attributing treatment failure to pharmacokinetic variability.

Key Trial Efficacy: The Numbers That Founded Each Drug's Approval

Sildenafil: The Goldstein 1998 NEJM Trial

The foundational approval trial for sildenafil was published by Goldstein et al. In the New England Journal of Medicine in 1998 (N=861 men with erectile dysfunction across a 24-week double-blind phase). At the 100 mg dose, 69% of all attempts at sexual intercourse were successful, compared with 22% on placebo (P<0.001). The mean score on the erectile function domain of the International Index of Erectile Function (IIEF-EF) rose from 11.7 at baseline to 21.0 at week 12. [2] That landmark dataset established the IIEF-EF as the standard outcome measure for all subsequent ED trials, including those for vardenafil.

Vardenafil: The Porst 2003 Trial

A key registration-quality trial for vardenafil was reported by Porst et al. In the International Journal of Impotence Research (2003, N=601 men with mild-to-severe ED in a 26-week double-blind phase). Vardenafil 20 mg produced a mean IIEF-EF score increase of 8.2 points over placebo (P<0.001), with 75% of intercourse attempts successful versus 32% on placebo. [3] The trial included a broad range of comorbidities, and response rates in diabetic men on vardenafil 20 mg reached 57%, a population in which sildenafil has historically shown attenuated response.

Direct Comparison of Efficacy Numbers

Neither the Goldstein nor the Porst trial was designed for head-to-head comparison. Comparing their absolute success rates directly is inappropriate because baseline severity differed between populations. What can be said with confidence: across independently conducted registration trials using the same IIEF-EF endpoint, both drugs produced clinically meaningful improvements (defined as a 4-point change in IIEF-EF) at their approved maximum doses.

Long-Term Durability: What 12-Month and Multi-Year Data Show

Durability of response is defined here as the sustained ability to achieve IIEF-EF scores consistent with successful intercourse through 12 months or beyond, without dose escalation or drug discontinuation due to loss of effect.

Sildenafil: 12-Month and Beyond

An open-label extension of the original key sildenafil trials followed 1,926 men for up to 2 years. IIEF-EF scores achieved in the blinded phase were maintained through the extension, with no evidence of tachyphylaxis (pharmacological tolerance) at the group level. [4] Importantly, continuation rates at 12 months exceeded 80% in the extension cohort, which is unusually high for a chronic medication and reflects both efficacy and tolerability. A 2013 systematic review in the Cochrane Database covering 82 trials (N=20,241 men) confirmed that sildenafil produced consistent, statistically significant improvement in IIEF scores across patient subgroups, with no signal of diminishing effect over time. [5]

Vardenafil: 12-Month Open-Label Data

Vardenafil's long-term durability data come primarily from a 12-month open-label extension study (N=1,089) presented alongside the European approval package. Men maintained on vardenafil 10 or 20 mg showed stable IIEF-EF scores throughout the 52-week follow-up. The "Global Assessment Question" response rate (the simple yes/no question "Did the treatment improve your erections?") remained above 80% at month 12 for men on 20 mg. [6] A separate 2-year follow-up in a German community-based cohort found that 74% of men who began vardenafil at year one were still taking it and reporting satisfactory intercourse at year two, a continuation rate comparable to sildenafil in similar real-world registries.

Diabetic ED: Where Vardenafil May Have a Durability Edge

Diabetes-associated ED is notoriously difficult to treat because autonomic neuropathy, endothelial dysfunction, and low nitric oxide bioavailability all compound the erectile deficit. A sub-study of the Porst 2003 dataset found vardenafil 20 mg produced a 53% success rate in diabetic men. A dedicated randomized controlled trial (N=452 men with type 2 diabetes) published in Diabetes Care in 2006 showed vardenafil 10 mg and 20 mg significantly improved IIEF-EF scores at 12 weeks (mean increases of 4.2 and 5.2 points, respectively) compared with 1.3 points for placebo (P<0.001 for both doses). [7] Long-term responder analyses in diabetic subgroups suggest that vardenafil may preserve more of its efficacy advantage over placebo at 6 to 12 months than sildenafil does in the same population, though no head-to-head diabetic durability trial has been published.

Tachyphylaxis: Does Either Drug Stop Working Over Time?

True pharmacological tachyphylaxis to PDE5 inhibitors is not documented in peer-reviewed literature at standard doses and with on-demand dosing. What is documented is psychological habituation, partner-dynamic changes, and progressive vascular disease eroding the neurogenic nitric oxide signal that both drugs depend on. When a man reports that his medication "stopped working" after years of effective use, the correct clinical response is to re-evaluate cardiovascular status, testosterone level, and medication list, not simply to increase the dose.

Head-to-Head Comparisons: What Direct Trial Data Exist?

Very few rigorous head-to-head trials of sildenafil versus vardenafil exist in the published literature, primarily because both were developed by competing companies with no commercial incentive to fund comparative research.

The Consensus Statement Gap

The 2018 American Urological Association (AUA) guideline on erectile dysfunction states:

"Clinicians should discuss the differences in pharmacological profile and patient preference factors when selecting among PDE5 inhibitors, as no high-level evidence consistently favors one agent over another in the general population."

That statement reflects the evidence gap accurately. For most men without complicating comorbidities, the choice between sildenafil and vardenafil should be driven by cost, formulation preference, and individual pharmacokinetic response. [8]

A 2004 Cross-Over Preference Study

A small cross-over preference study (N=150 men) published in European Urology in 2004 randomized men who had previously responded to sildenafil to a 4-week trial of vardenafil, then crossed back. Approximately 56% preferred vardenafil and 44% preferred sildenafil. The authors noted that the preference for vardenafil correlated with faster onset at 25 minutes in responders and fewer headache complaints. However, this preference study used self-report, not validated IIEF scoring, so clinical conclusions are limited. [9]

The HealthRX Clinical Decision Framework: Sildenafil vs Vardenafil

The following structured approach is used by the HealthRX medical team when a patient presents for PDE5 inhibitor selection or switching:

Step 1. Establish baseline IIEF-EF score before prescribing, to allow objective durability tracking at 3, 6, and 12 months.

Step 2. Default to sildenafil 50 mg for men without diabetes, significant cardiovascular disease, or a prior failed PDE5 inhibitor trial. Generic cost is typically $1 to $3 per dose; brand Viagra runs $60 to $90 per dose.

Step 3. Consider vardenafil first-line for:

• Men with type 2 diabetes and moderate-to-severe ED (IIEF-EF <17)
• Men who report sildenafil visual side effects (blue tinge, photophobia) on 100 mg
• Men who prefer an orodispersible tablet (Staxyn) for convenience or dysphagia
• Men taking medications that slow gastric motility (some antidepressants, opioids) where a faster onset form may help

Step 4. At each 3-month review, recalculate IIEF-EF. A drop of 4 or more points from peak response warrants metabolic re-evaluation (HbA1c, testosterone, lipid panel, blood pressure) before changing the molecule.

Step 5. Switching criteria. Switch from sildenafil to vardenafil if:

• Two consecutive failed attempts at 100 mg under optimal conditions (empty stomach, no alcohol, adequate arousal)
• IIEF-EF decline of 4 or more points from documented peak over 6 months without identifiable metabolic explanation
• Persistent visual side effects that reduce willingness to dose

Step 6. Trial the switch for 8 attempts (approximately 4 to 8 weeks for most couples) before concluding the alternative drug is non-superior.

Switching From Sildenafil to Vardenafil: Practical Guidance

When Switching Makes Sense

A man who achieves reliable erections on sildenafil 50 mg for three years and then notices declining rigidity over the following year is not necessarily experiencing tachyphylaxis. His vascular health or testosterone may have changed. Before switching molecules, a blood pressure check, HbA1c, and a morning testosterone level (drawn before 10 a.m.) should be completed.

Switching is appropriate when sildenafil fails under optimized conditions at its maximum approved dose of 100 mg. Starting vardenafil at 10 mg (not 20 mg) and titrating after 4 attempts gives the cleanest read on whether the new drug offers incremental benefit.

Starting Dose When Switching

Men switching from sildenafil 100 mg to vardenafil should generally start at vardenafil 10 mg rather than jumping to 20 mg. The 10 mg to 20 mg difference in vardenafil is analogous to the 50 mg to 100 mg step in sildenafil. Skipping the lower dose makes it harder to identify the minimum effective dose and increases headache and flushing rates unnecessarily.

Contraindications That Apply to Both Drugs

Both sildenafil and vardenafil are absolutely contraindicated with nitrate medications (nitroglycerin, isosorbide mononitrate, isosorbide dinitrate, amyl nitrite). Co-administration can cause severe, potentially fatal hypotension. Neither drug should be used in men taking riociguat. Vardenafil carries an additional caution for men with congenital QT prolongation or those taking class IA or III antiarrhythmics, because in vitro data suggest vardenafil may prolong the cardiac QT interval at supratherapeutic concentrations, an effect not documented for sildenafil. [10]

Cost, Availability, and Adherence Over Time

Generic Pricing and Adherence

Generic sildenafil has been available in the United States since December 2017, following patent expiration. Generic vardenafil followed in 2018. At the time of writing, generic sildenafil 100 mg tablets can be found at major US pharmacies for approximately $1.50 to $4 per tablet with a GoodRx coupon. Generic vardenafil 20 mg tablets typically run $3 to $8 per tablet with similar discounts. The cost differential matters for long-term adherence: a 2019 analysis in JAMA Internal Medicine found that out-of-pocket medication cost above $10 per dose was independently associated with PDE5 inhibitor non-adherence in men with employer-sponsored insurance. [11]

Insurance Coverage Patterns

Most US commercial insurance plans exclude PDE5 inhibitors for ED from standard formulary coverage, though some Medicare Part D plans have added generic sildenafil. Veterans Affairs pharmacy benefits include generic sildenafil at no copay for eligible veterans, a policy that has meaningfully improved adherence and follow-up rates in VA-based ED studies.

Side-Effect Profile Comparison and Long-Term Tolerability

Shared Side Effects

Both drugs produce headache (10 to 16% of users at standard doses), flushing (5 to 12%), nasal congestion, and dyspepsia. These effects are dose-dependent and generally attenuate over the first 4 to 6 doses as men adjust timing relative to meals and alcohol.

Where the Profiles Diverge

Sildenafil produces blue-tinge visual disturbance (cyanopsia) in approximately 3% of users at 100 mg, driven by PDE6 cross-reactivity. Vardenafil's higher PDE5 selectivity reduces but does not eliminate this. Non-arteritic anterior ischemic optic neuropathy (NAION) is an extremely rare but serious risk associated with PDE5 inhibitors as a class; the FDA added a black-box warning for all agents in 2005. [12] The absolute incidence remains <1 per 100,000 treated men per year across both drugs.

Vardenafil's theoretical QT-prolongation signal has not translated into documented clinical arrhythmia events in post-marketing surveillance through 2024, but the prescribing information retains the cautionary language. Clinicians should check the baseline QTc in men with cardiac history before starting vardenafil.

Back Pain

Tadalafil (Cialis) is the PDE5 inhibitor most strongly associated with back pain and myalgia, attributed to PDE11 inhibition. Neither sildenafil nor vardenafil has a clinically significant PDE11 affinity; back pain rates in trials of both drugs are similar to placebo. This distinction is worth making when a man switching away from tadalafil asks whether the alternative will carry the same side effect.

Special Populations: Older Men and Cardiovascular Comorbidity

Men over 65 represent a disproportionate share of ED diagnoses. Age-related reductions in hepatic blood flow and cytochrome P450 3A4 activity can increase plasma concentrations of both drugs. The approved prescribing information for sildenafil recommends starting at 25 mg in men aged 65 and older. Vardenafil's label recommends starting at 5 mg in the same age group. A 2015 population-based study in BJU International (N=3,921 men, median age 67) found that both drugs produced similar IIEF-EF score improvements in men over 65, though vardenafil users reported slightly lower rates of flushing, possibly reflecting the lower starting-dose recommendation guiding prescribers toward more conservative initial dosing. [13]

For men with stable coronary artery disease who are not on nitrates, the Princeton III Consensus (2012) classified PDE5 inhibitor use as low-risk when exercise tolerance exceeds 3 to 5 metabolic equivalents. Both sildenafil and vardenafil are acceptable in this risk stratum. Men on alpha-blockers for benign prostatic hyperplasia should separate their alpha-blocker and PDE5 inhibitor doses by at least 4 hours to reduce the risk of symptomatic hypotension.